Business
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100. The approva
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_LPn1dYo7pUzNzxgMYnmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/o_LPn1dYo7pUzNzxgMYnmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.","length":498,"tagName":"p"},{"type":"text","content":"The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and C” and permits the Company to proceed with Parts B and C.","length":285,"tagName":"p"},{"type":"text","content":"This milestone follows successful completion of earlier stages and reflects continued positive momentum at one of the world’s leading clinical research institutions.","length":165,"tagName":"p"},{"type":"text","content":"Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, commented, “This IRB approval represents another important step forward in our clinical development program for CMND-100. We are grateful to the Johns Hopkins team for their continued support and look forward to further demonstrating the potential of our non-hallucinogenic MEAI-based candidate for patients suffering from Alcohol Use Disorder.”","length":414,"tagName":"p"},{"type":"text","content":"About Clearmind Medicine Inc."...